title: Selection of patients for treatment of duodenal ulcer infected with Helicobacter pylori.
abstract: Ninety patients with endoscopically proven duodenal ulcer were followed for 1 year. All patients were initially treated with an H2-receptor antagonist. Those with more than two relapses within 1 year received triple therapy consisting of colloidal bismuth subcitrate, amoxicillin, and metronidazole. Results showed that 27 patients were symptom-free after one full course of H2 antagonist, 47 had one or two clinical recurrences, and 16 patients had more than two recurrences. Twelve of the latter group were Helicobacter pylori positive and were treated with triple therapy. We conclude that only a minority of duodenal ulcer patients needs to be treated with triple therapy; most of them can be treated with antisecretory agents.
authors.affiliation: Gastrointestinal Institute, Beilinson Medical Center, Petah Tiqva, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Neeman
authors.forename: U
authors.initials: U
authors.lastname: Kadish
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D018579:Patient Selection; D011899:Ranitidine / Q000627:therapeutic use; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D009942:Organometallic Compounds; D008795:Metronidazole; D002927:Cimetidine; D000658:Amoxicillin; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate